News

In preclinical models, the calcium release-activated calcium modulator inhibitors discovered by Synta potently and selectively inhibited the secretion of pro-inflammatory factors such as TNF-alpha and IL-2, with minimal

The company is currently enrolling patients in three separate protocols: two are randomized, controlled studies of patients with ACLF (acute-on-chronic liver failure) or FHF (fulminant hepatic failure). Continuous

Advaxis has submitted its investigational new drug (IND) application to the FDA in May 2008, which outlined the proposed protocol for a Phase II clinical trial safety study

AM211 is an oral, selective antagonist of the receptor DP2 (also known as CRTH2 or chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes). DP2 is a high affinity receptor

BioSante has received $3.32 million on signing with Azur, of which approximately $1.5 million was purchased inventory. Antares is entitled to 25% of any upfront and milestone payments

arGentis anticipates the confirmation process by the European Commission should be finalized in early 2009. Once confirmed, arGentis subsidiary, arGentis Autoimmune Europe, will gain access to incentives including

The Culex automated in vivo sampling system is designed to collect pharmacokinetic and pharmacodynamic (PK/PD) data during the course of drug metabolism experiments. The Culex systems can collect

Under the terms of the agreement, BioMarin will receive a co-exclusive license to develop and commercialize Riquent and La Jolla could receive up to $289 million in cash

The Phase I clinical trial is an open label, dose determination study which will be conducted in the US with approximately 24 hemodialysis patients in two treatment cohorts.